$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

$pvct Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223028230 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$69.73K	$161.8K	$321.7K
YoY Change	-77.85%	-49.69%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$360.0K	$380.1K	$455.9K
YoY Change	7.77%	-16.63%	14.67%
% of Gross Profit
Research & Development	$350.8K	$434.2K	$816.6K
YoY Change	-39.56%	-46.83%	35.44%
% of Gross Profit
Depreciation & Amortization	$10.00K	$2.230K	$2.820K
YoY Change	254.61%	-20.92%	-12.15%
% of Gross Profit
Operating Expenses	$783.9K	$962.0K	$1.400M
YoY Change	-20.1%	-31.27%	14.54%
Operating Profit	-$714.1K	-$800.2K	-$1.078M
YoY Change	7.2%	-25.77%	-11.79%
Interest Expense	-$60.00K	-$50.82K	-$38.10K
YoY Change	29.2%	33.39%	-91.65%
% of Operating Profit
Other Income/Expense, Net	-$61.69K	-$34.86K	$139.00
YoY Change	31.04%	-25178.42%	-100.04%
Pretax Income	-$780.0K	-$835.1K	-$1.078M
YoY Change	9.36%	-22.52%	-31.76%
Income Tax
% Of Pretax Income
Net Earnings	-$775.8K	-$835.1K	-$1.078M
YoY Change	8.77%	-22.52%	-31.76%
Net Earnings / Revenue	-1112.59%	-515.97%	-335.03%
Basic Earnings Per Share	$0.00	$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00	-$2.570K
COMMON SHARES
Basic Shares Outstanding	419.5M shares	419.5M shares	419.4M shares
Diluted Shares Outstanding	419.5M shares	419.5M shares	419.4M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$370.0K	$176.0K	$84.27K
YoY Change	451.99%	108.86%	77.75%
Cash & Equivalents	$367.3K	$1.359M	$84.27K
Short-Term Investments
Other Short-Term Assets	$1.220M	$1.398M	$2.192M
YoY Change	-33.4%	-36.22%	644.45%
Inventory
Prepaid Expenses			$243.4K
Receivables
Other Receivables
Total Short-Term Assets	$1.592M	$1.575M	$2.279M
YoY Change	-16.17%	-30.87%	556.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.25K	$16.48K	$25.80K
YoY Change	-37.99%	-36.12%	-78.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$97.76K	$111.3K	$164.7K
YoY Change	-35.28%	-32.39%	38.28%
TOTAL ASSETS
Total Short-Term Assets	$1.592M	$1.575M	$2.279M
Total Long-Term Assets	$97.76K	$111.3K	$164.7K
Total Assets	$1.690M	$1.687M	$2.443M
YoY Change	-17.57%	-30.97%	424.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.785M	$1.989M	$1.894M
YoY Change	-8.04%	5.02%	56.66%
Accrued Expenses	$3.240M	$3.049M	$2.457M
YoY Change	23.91%	24.12%	41.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$200.0K
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$3.070M	$2.751M	$1.953M
YoY Change	63.11%	40.87%	1432.84%
Total Short-Term Liabilities	$9.172M	$8.934M	$8.494M
YoY Change	3.94%	5.17%	176.06%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$40.00K	$49.98K	$96.20K
YoY Change	-52.95%	-48.05%
Total Long-Term Liabilities	$40.00K	$49.98K	$96.20K
YoY Change	-52.95%	-48.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.172M	$8.934M	$8.494M
Total Long-Term Liabilities	$40.00K	$49.98K	$96.20K
Total Liabilities	$9.209M	$8.983M	$8.590M
YoY Change	3.37%	4.57%	179.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$252.0M	-$251.3M	-$248.1M
YoY Change	1.27%	1.25%
Common Stock	$419.5K	$419.5K	$419.4K
YoY Change	0.01%	0.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.519M	-$7.297M	-$6.147M
YoY Change
Total Liabilities & Shareholders Equity	$1.690M	$1.687M	$2.443M
YoY Change	-17.57%	-30.97%	424.0%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$775.8K	-$835.1K	-$1.078M
YoY Change	8.77%	-22.52%	-31.76%
Depreciation, Depletion And Amortization	$10.00K	$2.230K	$2.820K
YoY Change	254.61%	-20.92%	-12.15%
Cash From Operating Activities	-$770.0K	-$617.8K	-$877.9K
YoY Change	-5.7%	-29.63%	10.91%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	820.0K	656.4K	430.4K
YoY Change	65.04%	52.54%	-12.12%
NET CHANGE
Cash From Operating Activities	-770.0K	-617.8K	-877.9K
Cash From Investing Activities
Cash From Financing Activities	820.0K	656.4K	430.4K
Net Change In Cash	50.00K	38.66K	-447.5K
YoY Change	-115.64%	-108.64%	48.26%
FREE CASH FLOW
Cash From Operating Activities	-$770.0K	-$617.8K	-$877.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity File Number EntityFileNumber	001-36457
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Central Index Key EntityCentralIndexKey	0000315545
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	PVCT	Rightofuse Asset For Lease Liability RightofuseAssetForLeaseLiability		usd
	PVCT	Conversion Of Notes And Related Accrued Interest ConversionOfNotesAndRelatedAccruedInterest		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Entity Registrant Name EntityRegistrantName	PROVECTUS BIOPHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0031917
	dei	Entity Address Address Line1 EntityAddressAddressLine1	800 S. Gay Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1610
	dei	Entity Address City Or Town EntityAddressCityOrTown	Knoxville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37929
	dei	City Area Code CityAreaCode	866
	dei	Local Phone Number LocalPhoneNumber	594-5999
	dei	Entity Information Former Legal Or Registered Name EntityInformationFormerLegalOrRegisteredName	Not Applicable
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	419522119	shares
CY2023Q2	us-gaap	Cash Cash	176010	usd
CY2022Q4	us-gaap	Cash Cash	21605	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1183149	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1410102	usd
CY2023Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	1461	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	394	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	214652	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	467081	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	1575272	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1899182	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	106534	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	102073	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16480	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20941	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	94851	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	117123	usd
CY2023Q2	us-gaap	Assets Assets	1686603	usd
CY2022Q4	us-gaap	Assets Assets	2037246	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1989372	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2094258	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1144091	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1510958	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2884204	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2404012	usd
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	4433	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	30844	usd
CY2023Q2	PVCT	Interest Payable To Related Parties Current InterestPayableToRelatedPartiesCurrent	114409	usd
CY2022Q4	PVCT	Interest Payable To Related Parties Current InterestPayableToRelatedPartiesCurrent	40992	usd
CY2023Q2	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	148273	usd
CY2022Q4	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	239394	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	75000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	625000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	46227	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	44422	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8933509	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8192380	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	49975	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	73376	usd
CY2023Q2	us-gaap	Liabilities Liabilities	8983484	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8265756	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	419497119	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	419497119	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	419497119	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	419497119	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	419497	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	419497	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	243548218	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	242954193	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-35766	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-35679	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-251251157	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-249588641	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-7296881	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6228510	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1686603	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2037246	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	161842	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	321710	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	366867	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	509315	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	434214	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	816648	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	982607	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1487764	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	527831	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	583042	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	966676	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1099589	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	962045	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1399690	usd
	us-gaap	Operating Expenses OperatingExpenses	1949283	usd
	us-gaap	Operating Expenses OperatingExpenses	2587353	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-800203	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1077980	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1582416	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2078038	usd
CY2023Q2	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	15965	usd
CY2022Q2	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	38259	usd
	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	15965	usd
	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	38259	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-50824	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-38120	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-96065	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-68984	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-34859	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	139	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-80100	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30725	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-835062	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1077841	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1662516	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2108763	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419497119	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	419497119	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419447119	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	419447119	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419497119	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	419497119	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419447119	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	419447119	shares
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-835062	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1077841	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1662516	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2108763	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-298	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-328	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-2799	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-1044	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-835360	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1078169	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1665315	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2109807	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6228510	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	54010	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-827454	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	191	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-7001763	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	540222	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-835062	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-278	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-7296881	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4187280	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	150000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1030922	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-716	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-5068918	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-5068918	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1077841	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-328	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-328	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-6147087	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-6147087	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1662516	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2108763	usd
	PVCT	Noncash Lease Expense NoncashLeaseExpense	22272	usd
	PVCT	Noncash Lease Expense NoncashLeaseExpense	31142	usd
	us-gaap	Depreciation Depreciation	4461	usd
	us-gaap	Depreciation Depreciation	6037	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1366	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2363	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-314165	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-143940	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-104704	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	606742	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-366866	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-509315	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	483019	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	329135	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-21597	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-37196	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	91239	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	65811	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1241893	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1470104	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	550000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1325000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	152856	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	153185	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1172144	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	396815	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-2799	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1044	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-72548	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1074333	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1431707	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3106942	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1359159	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2032609	usd
CY2023Q2	us-gaap	Cash Cash	176010	usd
CY2022Q2	us-gaap	Cash Cash	84274	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	1183149	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	1948335	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1359159	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2032609	usd
	us-gaap	Stock Issued1 StockIssued1	150000	usd
	PVCT	Rightofuse Asset For Lease Liability RightofuseAssetForLeaseLiability	130422	usd
	PVCT	Conversion Of Notes And Related Accrued Interest ConversionOfNotesAndRelatedAccruedInterest	594232	usd
	PVCT	Purchase Of Insurance Policies Financed By Shortterm Note Payable PurchaseOfInsurancePoliciesFinancedByShorttermNotePayable	-61735	usd
	PVCT	Purchase Of Insurance Policies Financed By Shortterm Note Payable PurchaseOfInsurancePoliciesFinancedByShorttermNotePayable	-57426	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_806_eus-gaap--NatureOfOperations_zBjSz3w7Uvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_82F_za24LPXmMdf4">Business Organization, Nature of Operations and Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or “the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (“HXs”). Our lead HX molecule is named rose bengal sodium (“RBS”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of our current clinical development programs and the preclinical formulations of our current drug discovery programs. Importantly, our pharmaceutical-grade RBS displays different therapeutic effects at different concentrations and can be formulated for delivery by different routes of administration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that RBS targets disease in a bifunctional manner. First, direct contact may lead to cell death or repair, depending on the disease being treated and the concentration of the RBS utilized in the treatment. Secondly, multivariate immune signaling, activation, and response may follow that may manifest as stimulatory, inhibitory, or both.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that it is the first entity to advance an RBS formulation into clinical trials for the treatment of a disease, such as those trials reported on the clinical trials registry at ClinicalTrials.gov.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that it is the first and only entity to date to successfully, reproducibly, and consistently make pharmaceutical-grade RBS at a purity of nearly 100%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s small molecule HX medical science platform comprises a number of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; <i>in vivo</i> proof-of-concept programs in oncology, hematology, wound healing, and animal health; and <i>in vitro</i> drug discovery programs in infectious diseases and tissue regeneration and repair.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks and Uncertainties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis of Presentation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2022 filed with the SEC on March 30, 2023. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1359159	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	1183149	usd
CY2023Q2	PVCT	Working Capital Deficit WorkingCapitalDeficit	7358237	usd
CY2022Q4	PVCT	Working Capital Deficit WorkingCapitalDeficit	6293198	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1662516	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2108763	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1241893	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1470104	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	161842	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	366867	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	321710	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	509315	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zXD4WvbggGL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zaLn50bcVFKf">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities and the valuation allowance related to the Company’s deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1183149	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zA0xsuAbybik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_z5aCK6USx2C7">Cash Concentrations</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20230630_zVByn5M22dT5" title="Insured limits">250,000</span>, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future. As of June 30, 2023 and December 31, 2022, the Company had cash and restricted cash balances in excess of FDIC insurance limits of $<span id="xdx_90C_eus-gaap--FDICIndemnificationAsset_iI_c20230630_zyUWl9q5Ps5b" title="Cash in excess FDIC insured amount">1,109,159</span> and $<span id="xdx_904_eus-gaap--FDICIndemnificationAsset_iI_c20221231_zoqpucJuFBy1" title="Cash in excess FDIC insured amount">1,181,707</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q2	us-gaap	Fdic Indemnification Asset FDICIndemnificationAsset	1109159	usd
CY2022Q4	us-gaap	Fdic Indemnification Asset FDICIndemnificationAsset	1181707	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	125324330	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	116330435	shares
CY2023Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	523600	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	314160	usd
CY2023Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	84131	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	69077	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2138089	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1945589	usd
CY2023Q2	PVCT	Accrued Other Expenses AccruedOtherExpenses	138384	usd
CY2022Q4	PVCT	Accrued Other Expenses AccruedOtherExpenses	75186	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2884204	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2404012	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	148273	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	239394	usd
CY2023Q2	us-gaap	Officers Compensation OfficersCompensation	96250	usd
	us-gaap	Officers Compensation OfficersCompensation	96250	usd
CY2022Q2	us-gaap	Officers Compensation OfficersCompensation	192500	usd
	us-gaap	Officers Compensation OfficersCompensation	192500	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2138089	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1945589	usd
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50
	us-gaap	Operating Lease Payments OperatingLeasePayments	21597	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	38625	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	151693	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.050	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	24994	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	50663	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	25669	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	101326	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5124	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	96202	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	46227	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	49975	usd
CY2021Q4	PVCT	Proceeds From Grant Award For Study Of Animal Cancer And Dermatological ProceedsFromGrantAwardForStudyOfAnimalCancerAndDermatological	2500000	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1144091	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1510958	usd
	PVCT	License Transaction Description LicenseTransactionDescription	The Company completed the arrangements of this collaboration during the third quarter of 2022, whereby the Company (i) paid $5,000 for the option to obtain an exclusive worldwide, royalty-bearing license that expires on May 31, 2023, (ii) agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option, (iii) agreed to pay up to $25,000 of past UM patent expenses for this IP, and (iv) entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and TOP PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis

Files In Submission

Name	View Source	Status
0001493152-23-028230-index-headers.html	Edgar Link	pending
0001493152-23-028230-index.html	Edgar Link	pending
0001493152-23-028230.txt	Edgar Link	pending
0001493152-23-028230-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pvct-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pvct-20230630_cal.xml	Edgar Link	unprocessable
pvct-20230630_lab.xml	Edgar Link	unprocessable
pvct-20230630_def.xml	Edgar Link	unprocessable
pvct-20230630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2023 Q3 Form 10-Q Financial Statement

#000149315223028230 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2023 Q3 Form 10-Q Financial Statement

#000149315223028230 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct